Literature DB >> 2920405

Lactate dehydrogenase isoenzyme pattern in sera of patients with malignant diseases.

E E Giannoulaki1, D L Kalpaxis, C Tentas, P Fessas.   

Abstract

Total lactate dehydrogenase (LDH; EC 1.1.1.27) activity and the percentage distribution of LDH isoenzymes were determined in 127 patients with malignant diseases. A shift in the isoenzyme patterns was observed toward the M-type, with an increase in the percentage of LDH-4 and LDH-5 isoenzymes and a slight increase in total LDH activity of all patients. Serum samples from 68 of the patients contained an abnormal isoenzyme of LDH, "LDH-1 ex," that, on agarose gel electrophoresis at pH 8.6, migrated between albumin and LDH-1 isoenzyme. Chemotherapy, radiotherapy, or surgical removal of the tumor was accompanied by disappearance of this abnormal isoenzyme. The heat stability of LDH-1 ex isoenzyme appears to be similar to that of LDH-1 but greater than that of the other LDH isoenzymes. Statistical analysis of these data demonstrated a significant correlation between malignancy and the appearance of LDH-1 ex isoenzyme (P less than 0.001). In contrast, the relationship between LDH-1 ex isoenzyme and metastasis or anatomical location of the malignancy is not statistically important (P less than 0.1).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920405

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Adjustments of serum lactate dehydrogenase isoenzymes and their significance in monitoring the treatment in patients with tubercular pyothorax.

Authors:  Riaz Ahmad; Mumtaz Alam; M Faisal Siddiqui; Absar-Ul Hasnain
Journal:  Indian J Clin Biochem       Date:  2008-06-11

2.  Importance of glycolysis and oxidative phosphorylation in advanced melanoma.

Authors:  Jonhan Ho; Michelle Barbi de Moura; Yan Lin; Garret Vincent; Stephen Thorne; Lyn M Duncan; Lin Hui-Min; John M Kirkwood; Dorothea Becker; Bennett Van Houten; Stergios J Moschos
Journal:  Mol Cancer       Date:  2012-10-09       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.